- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01373047
CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells (HITM)
Phase I Trial Of Intrahepatic Infusion Of 2nd Generation Designer T Cells For Cea-Expressing Liver Metastases
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
T cells have the power to destroy malignant cells under certain conditions, as demonstrated by the rare spontaneous remissions of cancer. However, the endogenous T cell response to cancer fails in the vast majority of patients and the tolerogenic conditions within the liver may pose additional immunologic barriers for those with intrahepatic metastases. The investigators modify patient T cells to kill malignant cells based on their expression of tumor antigens using antibody-defined recognition. The investigators will achieve this by preparing chimeric IgCD28TCR genes in mammalian expression vectors to yield "designer T cells" from normal patient cells. Prior studies in model systems demonstrated that recombinant IgCD28TCR could direct modified T cells to respond to antigen targets with IL2 secretion, cellular proliferation, and cytotoxicity - the hallmarks of an effective, self-sustaining immune response.
The present trial will test the regional infusion of anti-CEA designer T cells, given via the hepatic artery using a percutaneous approach. This is an intra-patient dose escalation trial, where patients will receive three doses over the course of six weeks. Doses are 10^8, 10^9 and 10^10 modified T cells. Patients are monitored for safety and response. Patients are on-study for one month after dosing.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02908
- Roger Williams Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of CEA+ adenocarcinoma and liver metastases
- Liver metastases must be CEA-expressing as demonstrated by elevated serum CEA levels (≥10ng/ml) or immunohistochemistry on a biopsy specimen
- Failure on at least one line of standard systemic chemotherapy and have unresectable liver disease
- Measurable liver disease (> 1.0 cm by CT or MRI)
- Extrahepatic disease is acceptable when limited to the lungs and/or abdominal lymph nodes
- At least 18 years of age
- Able to understand and sign informed consent
- Life expectancy of greater than four months
- Good performance status (PS 0-1)
Exclusion Criteria:
- Pregnancy
- Serious medical conditions including but not limited to liver, cardiopulmonary, and renal disease
- Patients with a history of portal hypertension, cirrhosis, hepatitis, or with radiographic evidence of cirrhosis
- Concurrent malignancy
- Use of systemic steroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intrahepatic anti-CEA designer T cells
|
Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the safety of modified T cells delivered into the hepatic artery by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Response by CT or MRI and PET scan
Time Frame: 1 month
|
CT or MRI and PET imaging will be obtained before the first infusion and following the final infusion to document changes in liver tumor size and metabolic activity.
|
1 month
|
Designer T cell distribution following infusion
Time Frame: 1 month
|
Using liver tumor biopsy specimens and blood collection, we will determine the extent to which infused T cells enter the liver tumors in addition to circulation in the extrahepatic space.
|
1 month
|
Designer T cell survival and phenotype following infusion
Time Frame: 1 month
|
Using tissue obtained from biopsies in addition to blood samples, the duration of T cell persistence will be assessed, in addition to cell surface markers.
|
1 month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Steven C Katz, MD, Roger Williams Medical Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RWH 335-99
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Metastases
-
Dr. M.R. MeijerinkAmsterdam UMC, location VUmcCompletedColorectal Liver Metastases | Metastatic Liver DiseaseNetherlands
-
Society of Interventional OncologyRecruitingColorectal Liver MetastasesUnited States, Netherlands, Greece
-
Memorial Sloan Kettering Cancer CenterCompletedLocalize Liver MetastasesUnited States
-
Heidelberg UniversityUnknownColorectal Liver MetastasesGermany
-
Peking University Cancer Hospital & InstituteRecruitingColorectal Liver MetastasesChina
-
Amsterdam UMC, location VUmcCompletedColorectal Liver MetastasesNetherlands
-
David BartlettNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedColorectal Liver MetastasesUnited States
-
University of MilanCompleted
-
M.D. Anderson Cancer CenterSanofiTerminatedColorectal Liver MetastasesUnited States
-
University of ZurichCompletedColorectal Liver MetastasesSwitzerland
Clinical Trials on anti-CEA 2nd generation designer T cells
-
Roger Williams Medical CenterWithdrawn
-
Roger Williams Medical CenterSuspendedMetastatic CancersUnited States
-
Roger Williams Medical CenterTerminated
-
Sorrento Therapeutics, Inc.WithdrawnBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic AntigenUnited States
-
Roger Williams Medical CenterUniversity of Colorado, Denver; Sorrento Therapeutics, Inc.Completed
-
Roger Williams Medical CenterSuspendedTrial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative ConditioningMonitor Adverse EventsUnited States
-
Roger Williams Medical CenterSirtex MedicalCompletedLiver MetastasesUnited States
-
Seattle Children's HospitalThe Evan Foundation; Ben Towne Center for Childhood Cancer ResearchActive, not recruitingNeuroblastoma | GanglioneuroblastomaUnited States
-
Roger Williams Medical CenterSuspendedBreast CancerUnited States
-
Changhai HospitalRecruitingColorectal Cancer | Metastatic Liver CancerChina